<DOC>
	<DOCNO>NCT00516425</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , epirubicin , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop divide . Giving combination chemotherapy surgery may kill tumor cell remain surgery . Sometimes , surgery , tumor may need treatment progress . In case , observation may sufficient . It yet know whether give doxorubicin epirubicin together cyclophosphamide effective observation treat old woman invasive breast cancer . PURPOSE : This randomized phase III trial study doxorubicin epirubicin cyclophosphamide see well work compare observation treat old woman invasive breast cancer .</brief_summary>
	<brief_title>Doxorubicin Epirubicin Cyclophosphamide Treating Older Women With Invasive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To provide evidence extend current standard care old woman invasive breast carcinoma treat adjuvant chemotherapy comprise doxorubicin hydrochloride epirubicin hydrochloride cyclophosphamide . - Compare relapse-free survival interval patient treat adjuvant chemotherapy v adjuvant chemotherapy . - Compare toxicity accelerate adjuvant chemotherapy pegfilgrastim support vs non-accelerated adjuvant chemotherapy . OUTLINE : This multicenter study . Patients stratify accord participate center indication endocrine therapy ( yes v ) . Patients randomize 1 2 arm . - Arm I ( observation ) : Patients receive adjuvant chemotherapy . - Arm II ( adjuvant chemotherapy ) : Patients randomize 1 2 chemotherapy regimen . - Accelerated adjuvant chemotherapy : Patients receive doxorubicin hydrochloride cyclophosphamide ( AC ) OR epirubicin hydrochloride cyclophosphamide ( EC ) day 1 pegfilgrastim day 2 . Treatment repeat every 2 week 4 course absence disease progression unacceptable toxicity . - Non-accelerated adjuvant chemotherapy : Patients receive AC EC day 1 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . Patients undergo tumor tissue blood sample collection biological , pharmacological , proteomic study . Samples initially use establish resource material available different research group . Samples also analyze use SELDI MALDI-ToF technology identify biological profile correlate prognosis predict response treatment . Quality life assess baseline , 6 week , 1 month , 6 month , 9 month , 12 month , 18 month , 24 month . After completion study treatment , patient follow every 6 month 2 year annually thereafter .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive breast carcinoma Primary operable breast cancer surgically treat wide local excision mastectomy clear margin ( &gt; 1 mm apart deep margin full thickness resection ) No 8 week since prior definitive surgery Earlystage disease evidence metastases clinically routine stag investigation No T4 and/or N3 disease Prior axillary staging require , include 1 following : Sentinel node biopsy Axillary sample clearance All nodepositive patient must axillary clearance radiotherapy axilla Must high risk relapse within 5 year ( risk factor evaluate clinician 's discretion ) No invasive breast cancer , systemically treat ductal carcinoma situ ( DCIS ) , solid tumor within past 5 year No prior hematologic malignancy melanoma Hormone receptor status : Estrogen receptor ( ER ) progesterone receptor ( PR ) negative OR ER/PRweakly positive ( e.g. , Allred/Quick score ≤ 5 OR H score ≤ 100 ) PATIENT CHARACTERISTICS : Female Postmenopausal Performance status 01 Hemoglobin &gt; 9 g/dL WBC &gt; 3,000/mm³ Platelet count &gt; 100,000/mm³ Bilirubin normal ( unless know Gilbert 's disease present ) Albumin normal AST ALT ≤ 1.5 x upper limit normal ( ULN ) Creatinine ≤ 1.5 x ULN Creatinine clearance &gt; 50 mL/min No active uncontrolled infection Must available routine longterm hospital followup Must normal cardiac function significant cardiac disease ECHO MUGA PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior preoperative endocrine therapy No prior systemic therapy breast cancer mantle radiotherapy No prior breastconserving surgery contraindication , decline postoperative radiotherapy No concurrent hormone replacement therapy ( HRT )</criteria>
	<gender>Female</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>